. Author manuscript; available in PMC: 2014 Aug 5.

Published in final edited form as: Expert Opin Emerg Drugs. 2011 Mar 22;16(3):407–423. doi: 10.1517/14728214.2011.568938

Table 4. Potency of FLT3 inhibitors.

FLT3-inhibitor	FLT3-ITD autophorphorylation, IC₅₀, medium (nM)	FLT3-ITD autophorphorylation, IC₅₀, plasma (nM)	Ref.
AC220	1	18.4	[97,98,106]
Tandutinib (MLN518)	6	~ 200	[93,96]
Sorafenib (BAY43-9006)	3	308 – 484	[62,106]
Sunitinib (SU11248)	1	NR	[98,106]
Midostaurin (PKC412)	3 – 6	1000 – 1800	[84,106]
Lestaurtinib (CEP-701)	2	700	[98,106]

FLT3: FMS-like tyrosine kinase 3; ITD: Internal tandem duplication; NR: Not reported.